Full commitment to understanding the medical needs of Lebanese women and provide the best solutions tailored for them
Lebanon, 2021 –Organon (NYSE: OGN), the only global company of its size focused on women’s health, chose to come to Lebanon during a time of crisis to support in reviving the health and economic sectors in Lebanon by launching its services that focus on providing the best treatments and medical solutions for Lebanese women and improving their health conditions in various fields. This launch, with its imperative timing, represents an opportunity to support the Lebanese health sector to regain its leading position in the region and the world, despite the challenges, raising hopes for the revival of the economic sector by creating job opportunities for many Lebanese and thus increasing growth. The company aims to create a better healthy environment for every woman, based on women’s positioning as a priority and the exceptional offerings it allocates to her, which is based on the absolute understanding of her needs, which enables Organon to address many unique areas that go beyond the stage of reproductive health and raise women’s health conditions to new limits.
Managing Director Ramy Koussa of Organon (Middle East, North Africa, and Turkey) in Organon, highlights the vision of the company, “As the MENAT region continues to grow and is expected to expand further in the coming years, we recognize the need to focus on women-specific health conditions and treatments that impact the everyday life of women. This launch will not only transform women’s healthcare, but will also create over 400 job opportunities across MENAT. With our expertise, products, and technology in women-related conditions, we want to influence change in the region and empower women to take charge of their health to live better lives.”
The Organon executive leadership team rang the opening bell at the New York Stock Exchange (NYSE) to mark the first day of active trading. Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE sharing powerful perspectives, voices and images. Dr. Layal Abi Zeid, Obstetrician and gynecologist, Sexologist, Head of IVF department in Clinique du Levant and main anchor in the TV show the doctors stated that, “Every woman must have at least once a year a free mandatory consultation explaining her role in the preventive medicine for her health and the health of her family”.
Women everywhere are invited to take the “microphone” to add their voice to the digital “Wall of Voices” at HereForHerHealth.com.
Organon Lebanon’s Lead, pharmacist doctor Manal Dhainy stated, “The current situation in Lebanon requires a unique approach to health and care for patients. The economic and social conditions in Lebanon can influence the bodies and minds of women in unique ways that can take a toll on their health. Our aim today is to support the communities in Lebanon by building a healthier tomorrow by creating more job opportunities as well as providing women and their families with the support they need to cater to women’s health. We are all here for her health.”
The three core pillars that lead Organon’s offerings in Lebanon include:
- Biosimilars: Actively building a strong foundation by broadening the reach of offerings into new geographies while expanding through new collaborations and into new disease areas.
- Women’s Health: With more than 140 therapies that are being investigated by multiple companies across the women’s health industry, our goal is to add value by identifying and advancing the most promising opportunities for women.
- Established Brands: Our portfolio of over 60 medicines span several areas including cardiovascular disease, respiratory conditions, non-opioid pain management and dermatology. This diverse set of products and trusted brands are critical drivers of Organon’s growth that will enable us to invest in new opportunities.
Organon has an international footprint that serves people in more than 140 markets, with nearly 80% of its approximately $6.5 billion in annual revenue generated outside the U.S. Organon believes it is well positioned for organic low-to-mid-single digit growth from its 2021 base of business. Their approach to innovation is led by patient needs and the use of extensive global capabilities in clinical development and patient safety with the greatest potential to impact women’s health. Sandy Milligan, Head of Organon Research & Development stated “Women have been told to accept and normalize their conditions as a part of life, Organon’s mission is to change this. We believe this approach will be very successful — we hope to discover the ability to identify diseases earlier, the ability to modify the course of diseases or healthcare conditions and to ultimately, improve the quality of life for women at all stages.”
Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.